Background: We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivity on these associations.
Methods: We included 242 CN (105(43%) abnormal amyloid), and 278 MCI individuals (183(66%) abnormal amyloid) from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). For 181 (EMIF-AD MBD) and 36 (ADNI) proteins with a synaptic annotation in SynGO, associations with word learning recall were analysed with linear models.
Results: Subsets of synaptic proteins showed lower levels with worse recall in preclinical AD (EMIF-AD MBD: 7, ADNI: 5 proteins, none overlapping), prodromal AD (EMIF-AD MBD only, 27 proteins) and non-AD MCI (EMIF-AD MBD: 1, ADNI: 7 proteins). The majority of these associations were specific to these clinical groups.
Conclusions: Synaptic disturbance-related memory impairment occurred very early in AD, indicating it may be relevant to develop therapies targeting the synapse early in the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877693 | PMC |
| http://dx.doi.org/10.1186/s13195-025-01703-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synaptic protein CSF levels relate to memory scores in individuals without dementia.
Alzheimers Res Ther
March 2025
Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.
Background: We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivity on these associations.
Methods: We included 242 CN (105(43%) abnormal amyloid), and 278 MCI individuals (183(66%) abnormal amyloid) from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). For 181 (EMIF-AD MBD) and 36 (ADNI) proteins with a synaptic annotation in SynGO, associations with word learning recall were analysed with linear models.
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.
Alzheimers Dement
October 2024
Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, UK.
Article Synopsis
- The study examined DNA methylation patterns in blood samples related to 15 key biomarkers of Alzheimer's disease, focusing on neuroinflammation and neurodegeneration effects.
- Using 885 samples from the EMIF-AD study, researchers identified significant differential methylation connected to CSF levels of YKL-40 and neurofilament light chain (NfL).
- Findings suggest a link between YKL-40 DNA methylation and genetic variants, with implications for understanding how DNA methylation influences protein levels relevant to Alzheimer's disease.
Synaptic protein CSF levels relate to memory scores in individuals without dementia.
Res Sq
July 2024
Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC.
Introduction: We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivity on these associations.
Methods: We included 242 CN (105(43%) abnormal amyloid), and 278 MCI individuals (183(66%) abnormal amyloid) from EMIF-AD MBD and ADNI. For 181 (EMIF-AD MBD) and 36 (ADNI) proteins with a synaptic annotation in SynGO, associations with word learning recall were analysed with linear models.
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease.
Alzheimers Dement
September 2024
Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Article Synopsis
- The study investigated the role of neurodegeneration markers (neurogranin, neurofilament light, and hippocampal volume) in Alzheimer's disease using cerebrospinal fluid proteomics.
- A small number of individuals exhibited both amyloid and tau pathology with either neurogranin or neurofilament light, showing distinct proteomic profiles based on these markers.
- The findings suggest that neurogranin might not be the best indicator of neurodegeneration and that different markers provide unique insights into the disease, helping refine staging beyond just amyloid and tau levels.
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer's disease patients from controls.
Mol Neurodegener
September 2023
German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Background: With the emergence of microglia-modulating therapies there is an urgent need for reliable biomarkers to evaluate microglial activation states.
Methods: Using mouse models and human induced pluripotent stem cell-derived microglia (hiMGL), genetically modified to yield the most opposite homeostatic (TREM2-knockout) and disease-associated (GRN-knockout) states, we identified microglia activity-dependent markers. Non-targeted mass spectrometry was used to identify proteomic changes in microglia and cerebrospinal fluid (CSF) of Grn- and Trem2-knockout mice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!